Distinct roles of arginases 1 and 2 in diabetic nephropathy

Sidney M. Morris, Hanning You, Ting Gao, Jean Vacher, Timothy K. Cooper, Alaa S Awad

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Diabetes is the leading cause of end-stage renal disease, resulting in a significant health care burden and loss of economic productivity by affected individuals. Because current therapies for progression of diabetic nephropathy (DN) are only moderately successful, identification of underlying mechanisms of disease is essential to develop more effective therapies. We showed previously that inhibition of arginase using S-(2-boronoethyl)-L-cysteine (BEC) or genetic deficiency of the arginase-2 isozyme was protective against key features of nephropathy in diabetic mouse models. However, those studies did not determine whether all markers of DN were dependent only on arginase-2 expression. The objective of this study was to identify features of DN that are associated specifically with expression of arginase-1 or <2. Elevated urinary albumin excretion rate and plasma urea levels, increases in renal fibronectin mRNA levels, and decreased renal medullary blood flow were associated almost completely and specifically with arginase-2 expression, indicating that arginase-2 selectively mediates major aspects of diabetic renal injury. However, increases in renal macrophage infiltration and renal TNF-α mRNA levels occurred independent of arginase-2 expression but were almost entirely abolished by treatment with BEC, indicating a distinct role for arginase-1. We therefore generated mice with a macrophage-specific deletion of arginase-1 (CD11bCre/Arg1fl/fl). CD11bCre/Arg1fl/fl mice had significantly reduced macrophage infiltration but had no effect on albuminuria compared with Arg1fl/fl mice after 12 wk of streptozotocin-induced diabetes. These results indicate that selective inhibition of arginase-2 would be effective in preventing or ameliorating major features of diabetic renal injury.

Original languageEnglish (US)
Pages (from-to)F899-F905
JournalAmerican Journal of Physiology - Renal Physiology
Volume313
Issue number4
DOIs
StatePublished - Oct 1 2017
Externally publishedYes

Fingerprint

Arginase
Diabetic Nephropathies
Kidney
Macrophages
Hyperargininemia
Messenger RNA
Albuminuria
Experimental Diabetes Mellitus
Renal Circulation
Wounds and Injuries
Fibronectins
Isoenzymes
Chronic Kidney Failure
Urea
Albumins
Economics
Delivery of Health Care

Keywords

  • Arginase
  • Macrophages

ASJC Scopus subject areas

  • Physiology
  • Urology

Cite this

Distinct roles of arginases 1 and 2 in diabetic nephropathy. / Morris, Sidney M.; You, Hanning; Gao, Ting; Vacher, Jean; Cooper, Timothy K.; Awad, Alaa S.

In: American Journal of Physiology - Renal Physiology, Vol. 313, No. 4, 01.10.2017, p. F899-F905.

Research output: Contribution to journalArticle

Morris, Sidney M. ; You, Hanning ; Gao, Ting ; Vacher, Jean ; Cooper, Timothy K. ; Awad, Alaa S. / Distinct roles of arginases 1 and 2 in diabetic nephropathy. In: American Journal of Physiology - Renal Physiology. 2017 ; Vol. 313, No. 4. pp. F899-F905.
@article{16a9f83f78a7470da505e42eb00938ef,
title = "Distinct roles of arginases 1 and 2 in diabetic nephropathy",
abstract = "Diabetes is the leading cause of end-stage renal disease, resulting in a significant health care burden and loss of economic productivity by affected individuals. Because current therapies for progression of diabetic nephropathy (DN) are only moderately successful, identification of underlying mechanisms of disease is essential to develop more effective therapies. We showed previously that inhibition of arginase using S-(2-boronoethyl)-L-cysteine (BEC) or genetic deficiency of the arginase-2 isozyme was protective against key features of nephropathy in diabetic mouse models. However, those studies did not determine whether all markers of DN were dependent only on arginase-2 expression. The objective of this study was to identify features of DN that are associated specifically with expression of arginase-1 or <2. Elevated urinary albumin excretion rate and plasma urea levels, increases in renal fibronectin mRNA levels, and decreased renal medullary blood flow were associated almost completely and specifically with arginase-2 expression, indicating that arginase-2 selectively mediates major aspects of diabetic renal injury. However, increases in renal macrophage infiltration and renal TNF-α mRNA levels occurred independent of arginase-2 expression but were almost entirely abolished by treatment with BEC, indicating a distinct role for arginase-1. We therefore generated mice with a macrophage-specific deletion of arginase-1 (CD11bCre/Arg1fl/fl). CD11bCre/Arg1fl/fl mice had significantly reduced macrophage infiltration but had no effect on albuminuria compared with Arg1fl/fl mice after 12 wk of streptozotocin-induced diabetes. These results indicate that selective inhibition of arginase-2 would be effective in preventing or ameliorating major features of diabetic renal injury.",
keywords = "Arginase, Macrophages",
author = "Morris, {Sidney M.} and Hanning You and Ting Gao and Jean Vacher and Cooper, {Timothy K.} and Awad, {Alaa S}",
year = "2017",
month = "10",
day = "1",
doi = "10.1152/ajprenal.00158.2017",
language = "English (US)",
volume = "313",
pages = "F899--F905",
journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",
issn = "0363-6127",
publisher = "American Physiological Society",
number = "4",

}

TY - JOUR

T1 - Distinct roles of arginases 1 and 2 in diabetic nephropathy

AU - Morris, Sidney M.

AU - You, Hanning

AU - Gao, Ting

AU - Vacher, Jean

AU - Cooper, Timothy K.

AU - Awad, Alaa S

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Diabetes is the leading cause of end-stage renal disease, resulting in a significant health care burden and loss of economic productivity by affected individuals. Because current therapies for progression of diabetic nephropathy (DN) are only moderately successful, identification of underlying mechanisms of disease is essential to develop more effective therapies. We showed previously that inhibition of arginase using S-(2-boronoethyl)-L-cysteine (BEC) or genetic deficiency of the arginase-2 isozyme was protective against key features of nephropathy in diabetic mouse models. However, those studies did not determine whether all markers of DN were dependent only on arginase-2 expression. The objective of this study was to identify features of DN that are associated specifically with expression of arginase-1 or <2. Elevated urinary albumin excretion rate and plasma urea levels, increases in renal fibronectin mRNA levels, and decreased renal medullary blood flow were associated almost completely and specifically with arginase-2 expression, indicating that arginase-2 selectively mediates major aspects of diabetic renal injury. However, increases in renal macrophage infiltration and renal TNF-α mRNA levels occurred independent of arginase-2 expression but were almost entirely abolished by treatment with BEC, indicating a distinct role for arginase-1. We therefore generated mice with a macrophage-specific deletion of arginase-1 (CD11bCre/Arg1fl/fl). CD11bCre/Arg1fl/fl mice had significantly reduced macrophage infiltration but had no effect on albuminuria compared with Arg1fl/fl mice after 12 wk of streptozotocin-induced diabetes. These results indicate that selective inhibition of arginase-2 would be effective in preventing or ameliorating major features of diabetic renal injury.

AB - Diabetes is the leading cause of end-stage renal disease, resulting in a significant health care burden and loss of economic productivity by affected individuals. Because current therapies for progression of diabetic nephropathy (DN) are only moderately successful, identification of underlying mechanisms of disease is essential to develop more effective therapies. We showed previously that inhibition of arginase using S-(2-boronoethyl)-L-cysteine (BEC) or genetic deficiency of the arginase-2 isozyme was protective against key features of nephropathy in diabetic mouse models. However, those studies did not determine whether all markers of DN were dependent only on arginase-2 expression. The objective of this study was to identify features of DN that are associated specifically with expression of arginase-1 or <2. Elevated urinary albumin excretion rate and plasma urea levels, increases in renal fibronectin mRNA levels, and decreased renal medullary blood flow were associated almost completely and specifically with arginase-2 expression, indicating that arginase-2 selectively mediates major aspects of diabetic renal injury. However, increases in renal macrophage infiltration and renal TNF-α mRNA levels occurred independent of arginase-2 expression but were almost entirely abolished by treatment with BEC, indicating a distinct role for arginase-1. We therefore generated mice with a macrophage-specific deletion of arginase-1 (CD11bCre/Arg1fl/fl). CD11bCre/Arg1fl/fl mice had significantly reduced macrophage infiltration but had no effect on albuminuria compared with Arg1fl/fl mice after 12 wk of streptozotocin-induced diabetes. These results indicate that selective inhibition of arginase-2 would be effective in preventing or ameliorating major features of diabetic renal injury.

KW - Arginase

KW - Macrophages

UR - http://www.scopus.com/inward/record.url?scp=85030553283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030553283&partnerID=8YFLogxK

U2 - 10.1152/ajprenal.00158.2017

DO - 10.1152/ajprenal.00158.2017

M3 - Article

C2 - 28446459

AN - SCOPUS:85030553283

VL - 313

SP - F899-F905

JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

SN - 0363-6127

IS - 4

ER -